The ISSCR Releases Summary of Meeting With UK Regulators on the Use of AI to Develop Stem Cell Therapies

AnnouncementsPolicy
Written By Kym Kilbourne

The International Society for Stem Cell Research (ISSCR) held its second Broader Scope Scientific Advice meeting with the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) on October 29, 2025, focusing on the use of artificial intelligence (AI) in developing stem cell therapies.

The session explored key topics including the current state and challenges of AI, machine learning, and digitalization systems for automation in cell and gene therapy; applications of AI in autologous iPSC-derived RPE cell therapy; and AI-based image analysis for in-process characterization and decision-making during iPSC generation.

Read the meeting summary.

‍About ISSCR
Across more than 80 countries, the International Society for Stem Cell Research (ISSCR) is the preeminent global, cross-disciplinary, science-based organization dedicated to advancing stem cell research and its translation to medicine.

Kym Kilbourne
Next

The ISSCR Urges Continued NIH Investment in Human Embryonic Stem Cell Research to Sustain Scientific Progress and Therapeutic Innovation